HALIFAX, Canada - February 20, 2018 - Researchers from the University of Manchester have published a review of breast density measurement methods in the journal Breast Cancer Research. The study clinically validates Densitas’ automated breast density measurement software as a practical solution for use in breast cancer risk models used to stratify patients based on their risk of breast cancer.
Breast density is assessed during mammography screening because high density is associated with an increased risk of cancer. This study demonstrates that while visual and semi-automated density assessments show strong relationships with breast cancer risk they are neither pragmatic nor practical for use in population-based screening.
“We are very pleased to see that our breast density measurement software has been independently validated to be strongly associated with breast cancer risk by this eminent research team from the University of Manchester,” said Mohamed Abdolell, CEO of Densitas. “Several upcoming scientific and poster presentations at ECR 2018 in Vienna (March 2-4, 2018) will further confirm the results of the Manchester study.”
Densitas’ automated breast density software, DM-Density, is a multi-vendor solution that seamlessly integrates into existing IT infrastructure and radiologists’ workflows and uniquely processes routinely archived standard digital mammograms on Picture Archiving Communications Systems. DM-Density is cleared for clinical use in Europe and Canada.
The study can be downloaded from BioMed Central at http://bit.ly/2EoXCjA .
About Densitas
Densitas develops advanced imaging analytics technologies powered by machine learning that deliver actionable insights at point-of-care for high quality personalized breast health. Our products address the key challenges facing breast imaging today, including mammography quality, workflow efficiencies, compliance with national guidelines and standards, and delivery of appropriate care at sustainable costs.
